Pinnacle 21 企业软件加快所有所提交的研究数据的监管审查
Princeton, N.J., 2021 年 10 月 28 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a five-year contract with Pinnacle 21 for ongoing software and related services support for the agency’s DataFit program. The DataFit program assesses data quality and performs data validation for standards compliance of all electronic clinical and non-clinical trial study submission data. This agreement is similar to the contracts awarded to Pinnacle 21 in 2015 and 2011 by the FDA. Pinnacle 21 was acquired by Certara in October 2021.
“We are honored by the FDA’s continued support of our Pinnacle 21 Enterprise software and partnership,” said William F. Feehery, PhD., CEO of Certara. “We are dedicated to making the drug development and submission process more efficient and user-friendly for regulatory agencies and biopharmaceutical companies, helping to get crucial new therapies to patients sooner.”
The DataFit custom implementation of Pinnacle 21 Enterprise meets the FDA’s data fitness assessment needs. The Pinnacle 21 Enterprise software enables the FDA to perform large-scale data validation and data quality reporting. FDA reviewers can assess and understand the quality of incoming submission data at a summary level in hours instead of the days or weeks required in a manual review.
“Regulatory agencies are embracing change and innovation to streamline the submission process. As the compliance standards are not easy to navigate, our software helps to automate validation and identify issues,” said Max Kanevsky, chief technology officer of Certara’s Software business unit. “Furthermore, beginning last month, the FDA is enforcing the technical rejection criteria, which are applicable to submissions to the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.”
The contract includes the use of the Pinnacle 21 Enterprise software by the FDA to perform data validation for its DataFit program as well as Operations and Maintenance through IT professional services to the FDA.
关于Certara
Certara利用生物模拟软件和技术加速药物开发，革新传统药物的发现和开发。Certara的客户覆盖全球1,650多家生物制药公司61个国家和地区的、领先学术机构和主要监管机构。
联系人：
Jieun W. Choe
jieun.choe@certara.com
媒体联系人：
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
